arrow
S

Salvatore Petta

University of Palermo
H指数:87
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Impact of the AISF STEPS ‐ MASH Algorithm: Real‐World Application in Tertiary Hepatology Practice

AISF STEPS‐MASH算法的临床影响:在三级肝病实践中的真实世界应用

2026-11-160
PRE
Reply to: Kang L, Ye T. Before Liver Stiffness Becomes the Single Early Prognostic Marker in MASLD, How Certain and How Additional Is the One-Year Change? Clin Gastroenterol Hepatol 2026 in press.

回复:康磊,叶婷。在肝硬度成为MASLD单一早期预后标志物之前,一年的变化有多确定和多额外?《临床胃肠病学与肝病学》2026年待发表。

2026-10-190
PRE
EP497 - ECE_3829 - Evaluating steroid profiles through sexual dimorphism to define metabolic phenotypes and identify advanced fibrosis in patients with MASLD

EP497 - ECE_3829 - 通过性二态性评估类固醇谱以定义代谢表型并识别MASLD患者的进展性肝纤维化

2026-08-100
OAAI
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study

MASLD中脂肪性肝炎和纤维化影像学及血清学诊断生物标志物的前瞻性验证:LITMUS影像学研究

2026-07-240
OA
Machine Learning Prediction of Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)

机器学习预测代谢功能障碍相关脂肪性肝病(MASLD)患者的肝纤维化

2026-07-200
OAAI
Liver Aging Index: A Noninvasive Score for Liver Biological Aging and Liver-Related Outcomes in Multicohorts

肝脏衰老指数:一种用于多队列肝脏生物衰老和肝脏相关结局的非侵入性评分

2026-05-310
OAAI
Effectiveness of a Model of Care Based on Fibrosis-4 and Liver Stiffness Measurement for the Screening of Patients With Type 2 Diabetes Mellitus at Risk of Advanced Liver Disease: Results From an Italian Prospective Multicenter Study

基于Fibrosis-4和肝脏硬度测量的护理模式对有进展性肝病风险的2型糖尿病患者的筛查有效性:来自一项意大利前瞻性多中心研究的结果

2026-02-014
PRE
Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement

代谢功能障碍相关脂肪性肝病且FIB-4与肝硬度测量结果不一致患者的组织学严重程度和肝脏结局

2026-01-011
PRE
New CLA3+/4 scores predict outcomes in MASLD

新CLA3+/4评分可预测MASLD的结局

2026-01-010
OA
Cardiovascular-kidney-metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD

心血管-肾脏-代谢综合征与MASLD患者肝纤维化进展及肝脏相关事件的风险

2025-12-010
PRE
The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease

与组织学相比,在代谢功能障碍相关的脂肪性肝病晚期慢性肝病患者中,预期-NASH模型对临床事件风险的分层效果更好。

2025-11-100
OAAI
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study

Younossi, Z.M.; de Avila, L.; Petta, S.; Hagström, H.; Kim, S.U.; Nakajima, A.; Crespo, J.; Castera, L.; Alkhouri, N.; Zheng, M.H.; 等. MASLD的纤维化、临床事件及死亡率的预测因素:全球MASLD研究的数据. 肝病学 2025. [Google Scholar] [CrossRef]

2025-11-013
PRE
Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD

长期血糖控制与肝硬度进展及肝脏相关事件风险的关系 (MASLD)

2025-10-100
PRE
Association between longitudinal weight change and clinical outcome in individuals with MASLD

MASLD个体中纵向体重变化与临床结局的关联

2025-10-012
PRE
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study

非侵入性试验在MASLD中的全球表现:G-MASLD研究的见解

2025-10-010
PRE
ITA-MASLD: A national observational study to characterize the profile of patients with MASLD in specialistic care in Italy

ITA-MASLD:一项全国性观察性研究,旨在描述意大利专科医疗中MASLD患者的特征。

2025-09-150
PRE